ACRO Biomedical Co Ltd
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally. It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. wa… Read more
ACRO Biomedical Co Ltd (ACBM) - Net Assets
Latest net assets as of September 2025: $-432.62K USD
Based on the latest financial reports, ACRO Biomedical Co Ltd (ACBM) has net assets worth $-432.62K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.32K) and total liabilities ($436.94K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-432.62K |
| % of Total Assets | -10007.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -148.6% |
| 10-Year Change | N/A |
| Growth Volatility | 89.13 |
ACRO Biomedical Co Ltd - Net Assets Trend (2015–2025)
This chart illustrates how ACRO Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACRO Biomedical Co Ltd (2015–2025)
The table below shows the annual net assets of ACRO Biomedical Co Ltd from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-312.85K | -6.06% |
| 2024-12-31 | $-294.97K | -160.65% |
| 2023-12-31 | $486.37K | 0.00% |
| 2022-12-31 | $486.37K | -24.44% |
| 2021-12-31 | $643.71K | -6.15% |
| 2020-12-31 | $685.87K | -14.08% |
| 2019-12-31 | $798.24K | -35.74% |
| 2018-12-31 | $1.24 Million | +142.93% |
| 2017-12-31 | $511.33K | +3556.57% |
| 2016-12-31 | $-14.79K | -151.66% |
| 2015-12-31 | $28.64K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ACRO Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3275894100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.04K | % |
| Other Components | $32.40 Million | % |
| Total Equity | $-294.97K | 100.00% |
ACRO Biomedical Co Ltd Competitors by Market Cap
The table below lists competitors of ACRO Biomedical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AUSTOCK GRP
BE:5A9
|
$30.05K |
|
Aberdeen Global IF Inc
NYSE MKT:FCO
|
$30.06K |
|
Koramco Energy Plus Reit Co Ltd
KO:357120
|
$30.09K |
|
SITC INTL HLDGS
BE:7S8
|
$30.10K |
|
SINGTEL 1000
BE:SIT4
|
$30.03K |
|
ARTPRICE COM (AJP.SG)
STU:AJP
|
$30.02K |
|
Braxia Scientific Corp
PINK:BRAXF
|
$30.02K |
|
AMERN VANGUARD CORP
BE:AVJ
|
$29.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACRO Biomedical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -294,972 to -294,972, a change of 0.
- Net loss of 101,146 reduced equity.
- Other factors increased equity by 101,146.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-101.15K | -34.29% |
| Other Changes | $101.15K | +34.29% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ACRO Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.01 | $0.00 | x |
| 2018-12-31 | $0.03 | $0.00 | x |
| 2019-12-31 | $0.02 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $0.01 | $0.00 | x |
| 2022-12-31 | $0.01 | $0.00 | x |
| 2023-12-31 | $0.01 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
| 2025-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ACRO Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-719.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -165.85% | 0.00% | 0.00x | 1.03x | $-50.35K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-41.95K |
| 2017 | -0.44% | -0.44% | 0.93x | 1.07x | $-53.38K |
| 2018 | 33.78% | 5.24% | 5.40x | 1.19x | $295.44K |
| 2019 | -46.55% | -192.01% | 0.21x | 1.17x | $-451.43K |
| 2020 | -17.12% | -17.07% | 0.69x | 1.46x | $-186.04K |
| 2021 | -1196.52% | -643.18% | 1.57x | 1.18x | $-7.77 Million |
| 2022 | -3263.24% | -2410.24% | 0.96x | 1.41x | $-15.92 Million |
| 2023 | -3263.24% | -2410.24% | 0.96x | 1.41x | $-15.92 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.80K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-71.65K |
Industry Comparison
This section compares ACRO Biomedical Co Ltd's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $40,676,390
- Average return on equity (ROE) among peers: -69.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACRO Biomedical Co Ltd (ACBM) | $-432.62K | -165.85% | N/A | $30.04K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |